All News
Pfizer veteran Phil Dormitzer will assume the role of Global Head of Vaccines beginning Friday.
Deciphera Pharmaceuticals announced it is restructuring with the intention of prioritizing clinical development of specific programs and streamlining its commercial operations.
One day after falsified information regarding its Phase I/II breast cancer data circulated online, Olema Pharmaceuticals released its topline data for a potential best-in-class complete estrogen receptor antagonist.
Adagio claims that none of the mutations found in Omicron are linked with escape from ADG20 neutralization in vitro.
Ablaze has aligned itself with RayzeBio, giving Ablaze a solid start with an in-licensing agreement to bring Rayze’s products to the greater China market.
Early tests of Regeneron’s antibody cocktail show it isn’t as effective against Omicron while a separate tests of Eli Lilly’s antibody cocktail also demonstrated the same.
The whole world is watching the news about Omicron, but it’s obvious that it will be a week or two before enough is known about the new variant of concern.
Elizabeth Holmes blames the allegations of investor fraud perpetrated by her blood-testing company Theranos at the feet of her former business partner Ramesh “Sunny” Balwani.
Scientists who built xenobots have discovered that the very same organisms they made in 2020 have the ability to create new versions of themselves by banding together.
The CDC has shifted its recommendation on adults getting a booster COVID-19 vaccine to now include everyone ages 18 years and older.
Starting your new pharmacy job can be scary, especially if you have never worked in a pharmacy before. Here is what to expect on your first day.
Many factors contribute to community-building COVID herd immunity. Are we close to having herd immunity against Covid-19? Can we achieve that? Let’s find the answer.
Are you looking for doctor careers in the pharma sector? Here is everything you need to know about how you can choose a reputable and growing pharma career.
Two biopharma companies developing therapeutics in the oncology space begin the week with strong signals in Phase II.
Sigilon Therapeutics announced it may have discovered the reason why its experimental cell therapy treatment for severe hemophilia A was placed on clinical hold by the FDA.
Omicron has caused the U.S. to install travel bans against several South African countries while vaccine makers rush to test their vaccines against it. For that news and more, continue reading.
The deal adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to its pipeline.
New York-based Turnstone Biologics announced it is partnering with the Moffitt Cancer Center to develop tumor-infiltrating lymphocyte (TIL) therapies.
Quell Therapeutics scooped up $156 million in a Series B round this week. The company utilizes regulatory T cells to treat a variety of autoimmune and inflammatory diseases.
Results from its GEM-3 trial on VYJUVEK demonstrated statistical significance in its ability to promote complete wound healing within six months compared to a placebo.